Currently Viewing:
Evidence-Based Diabetes Management December 2018
Clinical Evidence for and Cost-Effectiveness of Advanced Cellular Tissue Products for the Treatment of Diabetic Foot Ulcers
Robert S. Kirsner, MD, PhD
Time for a "New Goalpost" in Cardiovascular Outcomes Trials, Kosiborod Suggests
Mary Caffrey
After FDA Panel Vote, Some See Next Generation of Cardiovascular Safety Trials for Diabetes Drugs
Mary Caffrey
For Payers, Cost Is the Downside of Continuing Cardiovascular Outcomes Trials in Current Form
Kenneth Snow, MD, MBA
Contributor: Increasing Awareness About Peripheral Artery Disease Can Save Limbs and Lives
Foluso A. Fakorede, MD
A Paradigm Shift Highlights the Need to Reduce CV Risk in Diabetes
Robert A. Gabbay, MD, PhD, FACP
Guidelines Updates in Diabetes and Cardiovascular Disease
Mary Caffrey
Medical World News: Clinical Updates
Coverage by Mary Caffrey, Surabhi Dangi-Garimella, PhD, Jaime Rosenberg, Samantha DiGrande, and Kelly Davio
Currently Reading
Medical World News: Managed Care Updates
Coverage by Mary Caffrey, Surabhi Dangi-Garimella, PhD, Jaime Rosenberg, Samantha DiGrande, and Kelly Davio

Medical World News: Managed Care Updates

Coverage by Mary Caffrey, Surabhi Dangi-Garimella, PhD, Jaime Rosenberg, Samantha DiGrande, and Kelly Davio

Oral Semaglutide Offers Superior A1C Reduction, Weight Loss in PIONEER 5 Trial

Novo Nordisk announced in August 2018 that topline results for its phase 3a trial of oral semaglutide show the drug reduced glycated hemoglobin (A1C) and helped patients with type 2 diabetes (T2D) lose weight after 26 weeks. If successful, the drug would be the first glucagon-like peptide-1 (GLP-1) receptor agonist taken once daily as a tablet.

PIONEER 5 is one of 10 trials involving the study drug. An injectable form of semaglutide, sold as Ozempic, received FDA approval1 last year.

Results of the PIONEER 5 trial, which involved 324 people with T2D and moderate renal impairment, showed that those treated with 14 mg oral semaglutide saw an A1C reduction of 1.1% compared with 0.1% for placebo. The group taking the study drug lost 3.7 kg compared with 1.1 kg for placebo.

From an average baseline A1C of 8%, the share of people reaching the target A1C of 7% by week 26 was greater with oral semaglutide than with placebo: 64% versus 21%, respectively. A target of 7% is recommended by the American Diabetes Association and other major diabetes professional organizations, as well as the Joslin Diabetes Center.

According to the statement2 from Novo Nordisk, PIONEER 5 involved 2 statistical approaches:
  • A primary approach required by regulatory guidance that evaluates the drug’s effect, regardless of discontinuation of treatment or use of rescue medication. During the trial, 15% discontinued treatment due to adverse events, primarily nausea, compared with 6% who discontinued while taking placebo.
  • A secondary approach described the effect of the drug while on treatment, without the use of rescue medication.
The population in PIONEER 5 had T2D and moderate renal impairment inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.

“The results from PIONEER 5 showed that oral semaglutide is efficacious and has a solid safety profile in people with type 2 diabetes and moderate renal impairment, thereby further expanding the solid clinical profile of oral semaglutide,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer, Novo Nordisk.

“Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options,” he said. “If approved, oral semaglutide represents an efficacious new solution.”

References:
  1. Caffrey M. FDA approves Semaglutide, Novo Nordisk’s once-weekly GLP-1 for type 2 diabetes. The American Journal of Managed Care® website. ajmc.com/newsroom/fda-approves-semaglutide-novo-nordisks-onceweek- ly-glp1-for-type-2-diabetes. Published December 5, 2017. Accessed August 20, 2018.
  2. Oral semaglutide provides superior HbA1C and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial [press release]. Bagsvaerd, Denmark: Novo Nordisk; August 20, 2018. http://hugin.info/2013/R/2211959/862238.pdf?rel=0" . Accessed August 20, 2018.

Stricter Blood Pressure Guidelines Could Prevent Cardiovascular Events, but Debate Continues

A year ago, the American College of Cardiology (ACC), and the American Heart Association (AHA) updated new blood pressure guidelines1 that lowered the threshold, from 140/90 mm Hg to 130/80 mm Hg, at which some patients should be treated for hypertension.

A new study, published in the AHA journal, Circulation, found that guideline change could translate into 3 million fewer cardiovascular disease events over 10 years, compared with earlier guidelines.2 “Treating high blood pressure is a major public health opportunity to protect health and quality of life for tens of millions of Americans,” said lead author Adam Bress, PharmD, MS, assistant professor of Population Health Sciences at University of Utah Health, in a statement.3 “Achieving these lower goals will be challenging.”

But along with commentary, Bress’ study is just one among several that have come recently that show, despite a landmark National Institutes of Health (NIH) study in 2015 that seemed like a mandate for lower blood pressure targets, not everyone is on board. The new study additionally says that for the highest-risk cardiovascular patients, the new guidelines could result in an increase of treatment-related serious adverse events, which suggests the need for personalized care.

One challenge is the Western diet, which is cited as the cause of rising levels of obesity and diabetes around the world. The assumption that blood pressure must rise with age may not be true, and it may be more closely connected to what we eat.

In a study recently published4 in JAMA Cardiology compared the blood pressure of 2 remote South American tribes, one which had no exposure to Western dietary patterns and the other which had some exposure to processed foods with higher levels of salt. Despite similar genetic backgrounds, the tribe that consumed saltier foods had higher blood pressure. Many believe the real key to treating heart disease and diabetes is getting serious about dietary and nutrition policy.

Bress and his team calculated fewer events in middle-aged adults based on the 2017 blood pressure goals when compared with guidelines in the seventh report of the Joint National Committee, known as JNC7, as with the eighth report of the Joint National Committee (JNC8), which put the cutoff for hypertension at 140/90 mm Hg for patients younger than 60 and 150/90 mm Hg for those aged 60 or older.

Franz H. Messerli, MD, and Sripal Bangalore, MD, MHA, writing in the Journal of the American College of Cardiology recently explained how physicians are justifiably confused. They offer a case study of a 63-year-old female patient with blood pressure readings that average 148/86 mm Hg. Guidelines between ACC/AHA, which cover 25,000 cardiologists, and those of the European Society of Hypertension and European Society of Cardiology, which cover 75,000 physicians, are not in alignment.5

ACC/AHA guidelines say her blood pressure should be 130/80 mm Hg. The European guidelines say her blood pressure should be 140/90 mm Hg. However, guidelines for the American College of Physicians and the American Association of Family Physicians say she is just fine at 150/90 mm Hg. The guidelines also do not align on how many medications to use when starting treatment.

Ironically, all 3 guidelines are based on the same study, called SPRINT (Systolic Blood Pressure Intervention Trial). This was a large trial6 by the NIH that stopped early because it became clear that treating patients to a lower blood pressure target was resulting in fewer fatal cardiovascular events.

Despite this, the American College of Physicians and the American Association of Family Physicians guidelines insist that treating blood pressure to a target of 130/80 mm Hg across a population of older adults will result in “low-value care.”

Messerli and Bangalore see more frustration ahead. “The above hypertension guideline fiasco eloquently illustrates the potential shortcomings of dogmatic clinical directives and, if anything, is prone to increase the rift between those who preach, those who teach, and those who treat,” they wrote.

“Unless we make a concerted effort to do so, as the number of guidelines is increasing more rapidly than does iron-clad evidence, we are prone to see more and more schism among recommendations, confusion among physicians, and anxiety among patients,” the authors concluded.

References:
  1. Caffrey M. High blood pressure starts at 130/80, new guidelines say. The American Journal of Managed Care® website. ajmc.com/conferences/aha-2017/80-new-guidelines-say. Published November 13, 2017. Accessed November 19, 2018.
  2. Bress AP, Colantonio LD, Cooper RS, et al. Potential cardiovascular disease events prevented with adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline [published online November 19, 2018]. Circulation. doi: 10.1161/CIRCULATIONAHA.118.035640.
  3. New blood pressure guideline could prevent 3 million cardiovascular events over 10 years [press release.] Salt Lake City, UT: University of Utah Health; November 19, 2018. eurekalert.org/pub_releases/2018-11/uouh- nbp111618.php. Accessed November 19, 2018.
  4. Reinberg S. Must blood pressure rise with age? remote tribes hold clues. HealthDay website. consumer. healthday.com/circulatory-system-information-7/blood-pressure-news-70/must-blood-pressure-rise-wth-age-remote-tribes-hold-clues-739669.html. Published November 14, 2018. Accessed November 19, 2018.
  5. Messerli FH, Bangalore S. The blood pressure landscape: schism among guidelines, confusion among physicians, and anxiety among patients. J Am Coll Cardiol. 2018;72(11):1313-1316. doi: 10.1016/j.jacc.2018.07.026.
  6. Caffrey M. 5 things to know about the SPRINT study. The American Journal of Managed Care® website. ajmc.com/newsroom/5-things-to-know-about-the-sprint-study. Published November 13, 2015. Accessed November 19, 2018.

Amgen Announces 60% Reduction in List Price of PCSK9 Inhibitor Evolocumab

In alignment with the American Heart Association’s Value in Healthcare Initiative, Amgen has announced that the price of its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, evolocumab (Repatha), will be reduced by approximately 60%, from an annual price of about $14,100 down to $5850.

Evolocumab was approved in 20151 for use in addition to diet and maximally tolerated stain therapy in adult patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of low-density lipoprotein cholesterol. Its staunch competitor, Sanofi-Regeneron’s alirocumab (Praluent), was approved just a month prior to treat patients with familial hypercholesterolemia, as well as high-risk patients with demonstrated heart disease whose cholesterol has not been controlled with maximally tolerated statins.

However, the launch price of these drugs was a point of contention and debate for a while. Alirocumab also had an annual price tag of over $14,000.

An early report from the Institute for Clinical and Economic Review (ICER) proposed that the PCSK9 inhibitors should cost 85% less2 than what they were listed at. “Our draft report suggests that $2177 is the price that should serve as an alarm bell—if the cost is more than $2177 a year, drug companies, doctors, insurers, and other parties may need to work together to determine ways to limit the use of these drugs, find savings in other parts of the health care system, or adopt other measures to help make these drugs more affordable,” Steven D. Pearson, MD, MSc, the founder and president of ICER, had said about their analysis.

Earlier this year, Sanofi and Regeneron announced a deal3 that the companies struck with pharmacy benefit manager (PBM) Express Scripts, under which alirocumab was included in the PBM’s National Preferred Formulary and would cost much less than its $14,000 annual price tag for patients who purchase the drug through Express Scripts.

Become a Member to see the rest of this article and get access to all of our articles and resources. Membership is Free!

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!